FameWave Announces Clinical Collaboration with Bristol Myers Squibb for the Planned Phase 1/2 Trial in Non-Small Cell Lung Ca...
April 12 2019 - 7:49AM
FameWave Ltd. a privately held biopharmaceutical company
developing CM-24, which is being acquired by Kitov Pharma
Ltd. (NASDAQ/TASE: KTOV), today announced the signing of a
clinical collaboration with Bristol Myers Squibb Company (NYSE:BMY)
to evaluate the combination of CM-24, FameWave’s monoclonal
antibody targeting the novel immune checkpoint carcinoembryonic
antigen-related cell adhesion molecule 1 (CEACAM1), with nivolumab
(Opdivo®), a PD-1 inhibitor, in patients with non-small cell lung
cancer (NSCLC).
FameWave and Bristol Myers Squibb will coordinate on the
protocol design for the Phase 1/2 clinical trial in a well-defined
patient population with NSCLC. Under the terms of the agreement,
FameWave will fund and sponsor the study and Bristol Myers Squibb
will supply nivolumab.
“FameWave’s collaboration with Bristol-Myers Squibb, a global
leader in immuno-oncology, is a crucial step to begin evaluation of
CM-24 in combination with a PD-1 inhibitor,” said Dr. Michael
Schickler, chief executive officer of FameWave. “We look forward to
evaluating CM-24 in NSCLC since we believe it has a great potential
as a novel immune checkpoint to be used in combination therapies
for a variety of hard-to-treat cancers.”
About CEACAM1 and CM-24
CM-24 is a humanized monoclonal antibody directed against
carcinoembryonic antigen-related cell adhesion molecule 1
(CEACAM1), an immune checkpoint protein belonging to the Human CEA
(Carcino-Embryonic Antigen) protein family. Evidence has shown that
CEACAM1 is expressed on tumor lymphocytes and is up-regulated in
several cancer types. Preclinical studies have shown evidence that
CM-24 enhances the cytotoxic activity of tumor-infiltrating
lymphocytes (TILs) against various CEACAM1-positive tumor cell
lines. CM-24 is being developed for multiple oncological
indications according to the expression pattern of its target
protein.
As part of the recently announced agreement for the acquisition
of FameWave by Kitov Pharma Ltd. (NASDAQ/TASE: KTOV), cCAM
BioTherapeutics Ltd., a wholly owned subsidiary of Merck Sharp and
Dohme Corp., known as “MSD” in Israel, is returning the rights to
CM-24 to former cCAM shareholders and founders of FameWave,
following an initial Phase 1 dose ranging study of CM-24 as single
agent. Kitov’s acquisition of FameWave is pending completion
of certain closing conditions, including FameWave entering this
collaboration agreement for CM-24 with Bristol Myers Squibb.
Forward-Looking Statements and Safe Harbor
Statement
Certain statements in this press release are forward-looking
statements within the meaning of applicable securities laws.
Forward-looking statements can be identified by the use of
forward-looking words such as "believe", "expect", "intend",
"plan", "may", "should", "could", "might", "seek", "target",
"will", "project", "forecast", "continue" or "anticipate" or their
negatives or variations of these words or other comparable words or
by the fact that these statements do not relate strictly to
historical matters. You should not place undue reliance on these
forward-looking statements, which are not guarantees of future
performance. Forward-looking statements reflect our current views,
expectations, beliefs or intentions with respect to future events,
and are subject to a number of assumptions, involve known and
unknown risks, many of which are beyond our control, as well as
uncertainties and other factors that may cause our actual results,
performance or achievements to be significantly different from any
future results, performance or achievements expressed or implied by
the forward-looking statements. Any forward-looking statement in
this press release speaks only as of the date which it is made. We
disclaim any intention or obligation to publicly update or revise
any forward-looking statement, or other information contained
herein, whether as a result of new information, future events or
otherwise, except as required by applicable law.
For further information, contact: Dr. Michael
Schickler CEO
972 8 932 4000
Kitov Pharma (NASDAQ:KTOV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kitov Pharma (NASDAQ:KTOV)
Historical Stock Chart
From Apr 2023 to Apr 2024